ABVC BioPharma, Inc. (NASDAQ: ABVC) announced today that its oncology partner OncoX BioPharma, Inc. has completed a USD 100,000 licensing payment pursuant to the existing licensing agreement. This transaction marks the fifth licensing payment made by OncoX in 2025, bringing total payments to USD 695,950 and further advancing ABVC's multi-partner licensing strategy and the execution of its oncology revenue framework.
OncoX BioPharma is a U.S.-based biotechnology company specializing in developing plant-derived oncology therapeutics. Its lead candidate, derived from Grifola frondosa (maitake mushroom) extract, has shown potential in treating triple-negative breast cancer, non-small-cell lung cancer, pancreatic cancer, and myelodysplastic syndrome (MDS). OncoX also collaborates with several Japanese biomedical companies and academic institutions to co-develop Precision Gene-Oriented Therapies and Anti-Fibrosis Technologies, combining stem-cell and immunotherapy platforms to accelerate clinical validation and expand global applications.
ABVC's three-tier value-amplification model highlights short-term licensing payments totaling USD 695,950 received to date, demonstrating cash-flow visibility and consistent milestone execution. In the long term, ABVC expects a 5% royalty on net sales up to a cumulative USD 55 million, creating a sustainable, high-profit-margin recurring income stream. Through this model, ABVC is transitioning from a traditional research-focused company into an asset-light, cash-visible international licensing platform with scalable and more predictable returns.
Based on consolidated data across all licensing partners, ABVC's total contractual cash revenue pool has the potential to reach up to USD 14.25 million, with USD 2.14 million received as of October 2025. Dr. Uttam Patil, ABVC's Chief Executive Officer, stated: "The continued licensing payments from OncoX reflect the progress and execution of our partnership strategy. This collaboration illustrates the effectiveness of ABVC's licensing-driven business model in transforming R&D assets into recurring value creation for both investors and patients."
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. It has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has received four INDs approved by the U.S. FDA. OncoX is also expanding into cancer-supportive care and preventative health through proprietary natural ingredients, having acquired the Lycogen® extraction platform to enter adjacent fields including preventative medicine, chronic disease care, aesthetic medicine, and animal health. These cross-sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
